Español
Nederlands
Italiano
Deutsch
Français
Português
In this section of the page, you will find all the information you need to understand how General Electric (GE) dividends work. In addition, you will be able to consult the payment date, the ex-dividend date, the last day to be entitled to the payment, the money to be received per share, the yield and any other doubts that may arise.
General Electric will distribute 0,08 dollars per share in the form of a dividend on January 23, 2024.
The December 25, 2023 is the ex-dividend date. So if you wish to receive General Electric dividends, you must buy one day before this date.
General Electric distributed 0.08 dollars per share in the form of a dividend on October 25, 2023.
General Electric Company, listed on the New York Stock Exchange as GE, has more than fifty years in the market, canceling dividends to its shareholders in a stable and consecutive manner, although with various fluctuations in the amount deposited, which in general terms can be considered progressive.
The Board of Directors together with the GE Shareholders' Meeting decide the timing and the annual installment to be delivered to its investors, being regularly between the 25th to 28th of the months of January, April, July and October of each year, so its periodicity is quarterly, making cash payments in four installments, with an estimated yield of 0.37% and a Price Earnings Ratio of 13.72.
Join +33,000 investors who get notifications, analysis and news.
Payout Ratio General Electric Dividends
The dividend payout ratio, also known as the payout ratio, is an essential indicator for assessing the stability of a company's dividends. This ratio shows what proportion of the company's net profit is used to pay dividends to shareholders.
Dividend payout ratio = Total dividends ÷ Net income
An appropriate payout ratio may vary depending on the industry, the company's growth stage and its financial health.
Dividend calendar of General Electric
This is the Dividend Calendar of General Electric in 2023.
| Event | Day |
|---|---|
| Last trading date | December 22, 2023 |
| Ex-Dividend (Ex-Date) | December 25, 2023 |
| Record date | January 22, 2024 |
| Date of payment | January 23, 2024 |
Our policy is based on extracting all the financial information available for each company so that our own algorithms weight this information, thus giving us a result as close as possible to the real data.
Historical annual dividend yields of Pharming Group
For a company to have growing dividends by our standards, the annual dividend amount must have increased steadily for at least the last 5 years.
Dividend yield of General Electric vs. the sector
The company's dividend yield is compared to the industry average to determine its positioning.
Imagine you have a list of dividend yields for different companies in an industry. If you look for the "top 25%% percentile", you will find a number. This number tells you that the top 25%% of the companies with the highest dividends have a yield higher than that number.
On the other hand, the "top 75%% percentile" shows you another number, which tells you that 75%% of the companies have a higher yield than that number, thus showing a more common and less high yield.
Dividend yield history in Pharming Group
For a company to have stable dividends by our standards, it is vital that it has not had an annual decline of more than 10% over the previous year.
Dividend history of Pharming Group
Pharming Group has never distributed dividends, so it has an empty dividend history.
General Electric dividend capture strategy
Information about General Electric
Pharming Group N.V., es una empresa con presencia mundial dedicada al sector biofarmacéutico, especialmente en la investigación y creación de tratamientos para enfermedades raras o poco comunes, debilitantes y con alto porcentaje de mortalidad.
Su sede principal se ubica en Leiden, en los Países Bajos y en Nueva Jersey, Estados Unidos, aunque atiende aproximadamente 30 mercados distribuidos entre Europa, Oriente Medio, América del Norte, África y Asia, contando con más de 300 empleados.
El grupo se aboca a comercializar terapias basadas en el reemplazo de proteínas, así como medicamentos de precisión, teniendo socios en cualquier nivel o parte interesada, desde pacientes, profesionales del sector de la salud, empleados, laboratorios pequeños, proveedores, accionistas externos, entre otros.
Entre sus medicamentos más representativos se encuentra el RUCONEST® (conestat alfa) y el JOENJA® (leniolisib), aprobados ambos por la EMA (Agencia Europea de Medicamentos) para ser comercializado en Europa, por la FDA (Administración de Alimentos y Medicamentos) para los Estados Unidos y por la MHRA (Agencia Reguladora de Medicamentos y Productos Sanitarios) para el Reino Unido.
Su plataforma tecnológica se basa principalmente en el uso de rhC1INH, aunque trabajan en el desarrollo o adquisiciones de otros métodos para ser usado en sus procesos, además también poseen en su plataforma como parte de sus servicios el monitoreo y oportunidad de reportar cualquier evento adverso, tratando de cumplir con los requisitos de atención sanitaria mundial y de actualizar sus productos.
Adicionalmente desarrollan programas para el tratamiento del síndrome ADPS (plaqueta pegajosa) la cual es una inmunodeficiencia anormal, genética y progresiva, así como la investigación, creación y comercialización del OTL-105, una terapia genética que actúa con células madre para tratar el angioedema hereditario (AEH), la cual se elabora en colaboración con Orchard Therapeutics.
Frequently asked questions about General Electric dividends
General Electric is listed on the New York Stock Exchange and is part of the Nyse.
General Electric has the Ticker or stock code GE.
At this moment, the value of a General Electric share is 0.00$.
General Electric does not have a growing dividend program. Dividends have not shown a steady growth in the last 5 years.
